{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.5","upperLimit":"14.5","value":"10.2"},{"groupId":"OG001","lowerLimit":"3.8","upperLimit":"8.2","value":"5.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"OS is defined as the time from the date of randomization until the date of death due to any cause in the PD-L1 positive population, defined as vCPS ≥10%.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"OG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"OG001","title":"Investigator Chosen Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The PD-L1 positive population included all randomized participants with tumor PD-L1 vCPS ≥10%","reportingStatus":"POSTED","timeFrame":"Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)","title":"Overall Survival (OS) in the PDL-1 Positive Analysis Set","type":"SECONDARY","unitOfMeasure":"Months"}